Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Facing Nasdaq Delisting

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies said on Friday that it has received notification from the Nasdaq that its stock faces delisting for failing to meet the exchange's $1 minimum bid price requirement.

Genetic Technologies said it has until Jan. 15, 2018 to regain compliance by meeting or exceeding the $1 per share price for 10 consecutive business days. If the firm fails to do so, but meets the Nasdaq's other listing requirements and presents a notice of its intent to regain compliance with the minimum bid requirement, it may be granted an additional 180 days before its shares are delisted.

The Nasdaq notification comes a few months after Genetic Technologies changed the pricing and billing structure for its breast cancer risk assessment test due to difficulties gaining adequate payment using a traditional payment model.

During early morning trading today, shares of Genetic Technologies were down about 2.5 percent at $.8776.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.